Relative potency of prorenoate and spironolactone in normal man.
Clin Pharmacol Ther, 1975/10;18(4):391-400.
Ramsay L, Harrison I, Shelton J, Tidd M
PMID: 1100306
Impact factor: 6.903
Abstract
The potency of single doses of a new aldosterone antagonist, prorenoate, in reversing the renal effects of the synthetic mineralocorticoid fludrocortisone was compared to that of spironolactone in a double-blind balanced crossover study in 12 healthy subjects. The potency of prorenoate potassium as related to elevation of the urinary log 10 10 Na/K ratio (2.69:1) and as related to potassium retention (3.75:1) was significantly higher than that of spironolactone. Prorenoate produced greater natriuresis (1.64:1) but the difference was not significant. There was evidence for a qualitative difference between spironolactone and prorenoate; the latter significantly more potent in retaining potassium than in increasing sodium excretion. The simple methodology described is based on standard bioassay principles, yielded a valid and sensitive comparison of the two drugs, and should prove useful in the evaluation of other aldosterone antagonists.
MeSH terms
Adolescent; Adult; Canrenoic Acid; Clinical Trials as Topic; Creatinine; Dose-Response Relationship, Drug; Fludrocortisone; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Pregnadienes; Sodium; Spironolactone
More resources
EndNote: Download